It has been a tough period for CSL Ltd (ASX: CSL) shares.
The biotechnology giant's shares ended the week at $143.19, which leaves them trading close to multi-year lows.
Is this an opportunity to invest $10,000 into the fallen giant? Let's take a closer look.
Image source: Getty Images
Why are CSL shares down?
There is no single reason behind CSL's recent weakness. Instead, it has been a combination of factors weighing on sentiment.
The biggest source of frustration has been CSL Behring, the company's core plasma therapies business. Margin recovery has taken longer than expected since the pandemic.
At the same time, its Seqirus vaccines business has faced softer demand, particularly in the United States, where influenza vaccination rates have come in below expectations.
China has also added to the pressure. Demand for albumin products has been weaker, which has impacted volumes at a time when investors were already becoming more cautious.
On top of this, the sudden exit of its CEO and its most recent result did little to calm nerves. A recent Morgans note commented:
1HFY26 result was softer and less clean than expected, with adjusted NPATA declining 7% and revenue modestly below forecasts. The result was further complicated by US$1.1bn in impairment charges, largely relating to Vifor and Seqirus, weighing on statutory earnings and sentiment.
Is this a buying opportunity?
Despite all of the above, there are reasons to believe CSL's long-term story remains intact.
Demand for its life-saving therapies is not cyclical in the same way many other industries are. Plasma-derived treatments are essential for patients around the world, and that demand is expected to grow steadily over time.
The company also continues to invest heavily in research and development, which supports a pipeline of new therapies and future revenue streams. This has been a key driver of its success over decades and is likely to continue being the case long into the future.
Importantly, many of the current challenges appear operational rather than structural. Cost pressures, vaccine demand fluctuations, and China weakness may weigh on near-term results, but they are not necessarily permanent.
If its new CEO can execute on its recovery plans, CSL's earnings growth could begin to normalise again over the coming years.
So, yes or no?
For investors with a long-term mindset, I think the answer is yes.
Morgans certainly thinks that is the case. In its note, it adds:
Importantly, FY26 guidance was maintained, despite Behring weakness and heightened scrutiny following the announced CEO transition, suggesting a 2H recovery, pointing to an execution reset, not structural impost, in our view. The outlook looks supported through a combination of cost-outs, marketing initiatives, new product launches and diminishing headwinds, reinforced by the Board's urgency around operational delivery. We adjust FY26-28 forecasts modestly, with our PT decreasing to A$241.34. BUY.
Based on the current share price, Morgans price target implies potential upside of almost 70%.
All in all, CSL shares are not without risks and patience will likely be required. But with its shares trading well below historical levels and the business still underpinned by strong global demand, this could be a compelling buying opportunity.
